EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Zhejiang University

Status: Completed

Conditions: Non-Small-Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage III

Treatments: Other: ARMS; Genetic: ctDNA analysis; Other: mutation detection

Study type: Observational

Funder types: Other

Identifiers

NCT02623257

20154701

Details and patient eligibility

About

The study aims to explore the prevalence of EGFR mutations assessed with ctDNA samples in advanced NSCLC, who had received ≤ 1 prior systemic chemotherapy regimens.

Enrollment: 1,055 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed stage IIIB/IV NSCLC;
• Patient had received ≤ 1 prior systemic chemotherapy regimens;
• Provision of blood (plasma) sample for ctDNA testing;
• Patient must be able to comply with the protocol;

Exclusion criteria

• Prior received ≥2 systemic chemotherapy regimens;
• As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease);
• Histologically confirmed small cell lung cancer or other metastatic tumors;
• Patient with no histologic or cytological diagnosis;